Showing results (181-190 of 214) with videos related to

Sort By:
Pageof 22
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 25, 2020
Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery DiseaseNandini M Meyersohn, Thomas Mayrhofer, Kathleen E Corey, et al.
Hepatology Communications|October 27, 2023
Effect of combined tobacco use and type 2 diabetes mellitus on prevalent fibrosis in patients with MASLDOluwafemi Balogun, Jeffrey Y Wang, Emad S Shaikh, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 21, 2026
Hepatic Steatosis Is Associated With Increased Cardiovascular Risk Through Adverse Coronary Plaque Composition: Insights from the PROMISE TrialJan M Brendel, Thomas Mayrhofer, Nóra M Kerkovits, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 20, 2019
Barriers to Use of Palliative Care and Advance Care Planning Discussions for Patients With End-Stage Liver DiseaseNneka N Ufere, John Donlan, Lauren Waldman, et al.
Alimentary Pharmacology & Therapeutics|December 29, 2023
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United StatesSamer Gawrieh, Eduardo Vilar-Gomez, Tinsay A Woreta, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 10, 2019
Physicians' Perspectives on Palliative Care for Patients With End-Stage Liver Disease: A National Survey StudyNneka N Ufere, John Donlan, Lauren Waldman, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 12, 2021
Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein KinaseShadi Salloum, Andre J Jeyarajan, Annie J Kruger, et al.
Plos One|February 10, 2023
Non-alcoholic fatty liver disease is not associated with impairment in health-related quality of life in virally suppressed persons with human immune deficiency virusSamer Gawrieh, Kathleen E Corey, Jordan E Lake, et al.
JCI Insight|July 24, 2020
Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLDLindsay T Fourman, James M Billingsley, George Agyapong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 14, 2021
Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver DiseaseTakara L Stanley, Lindsay T Fourman, Lai Ping Wong, et al.
Pageof 22